If you walk into a branch of Boots, there is most likely a good Apotheke branded antiviral hand foam on display.
Hand sanitisers are the first choice today, products are flying off the shelves and boots continue to limit sales due to high demand.
However, not all hand cleaners are created equal. Many are short-lived, some are antibacterial so there is no guarantee that they will have an effect on the coronavirus, and most are based on alcohol, which can irritate the skin, especially in humans. with diseases like eczema.
Rash - Many disinfectants are removed because they are irritating or ineffective, but the NHS uses Byotrol
The boot foam is durable, works against viruses and bacteria and does not contain alcohol. It is produced by Byotrol, a fast growing AIM listed company based in Chester.
Byotrol shares are at 5.9 cents and have risen sharply since the outbreak of the Covid-19 pandemic. However, there are many more miles in stock as attitudes towards hygiene changes and regulations in the plumbing sector tighten.
The industry is huge. According to independent consultants, global sales of antiviral and antibacterial products are around £ 50 billion a year, including sprays for kitchen counters, office countertops, factory production lines and more. Hospitals.
Byotrol operates in a small portion of this market, but its products are based on rigorous scientific research and are highly valued by customers such as Boots, NHS and Rentokil.
Rigor is becoming increasingly important in today's environment. American regulations have been extremely strict for years. Now the European Union and UK are catching up, restricting ingredients that can make the skin worse, harm the environment or make exaggerated claims about its effectiveness.
Several companies have already had to recall products from the market. Others should follow.
Byotrol is well placed to benefit from this climate. Managing Director David Traynor studied geography at Oxford and spent the first part of his career in banking, but surrounded himself with top academics and invested heavily in research and development.
This means that Byotrol works well with regulators and customers. In the USA, for example, Byotrol was the first company to receive regulatory approval for a long-lasting germ spray, Byotrol 24.
Procter & Gamble later launched a rival, but Byotrol got there first and the spray is so popular that it was temporarily out of stock in the US market.
However, the majority of Traynor's sales are generated in the UK. The company focuses on four areas here: hand disinfectants, workplace cleaners, sprays for medical practices and hospitals, and animal health products. .
As in the US, demand has exploded in all areas. All companies know they need to ensure that work areas are as sterile as possible so that employees can feel safe when they return to the office or the manufacturing facility.
Surgery, nursing homes and hospitals are more determined than ever to maintain strict hygiene.
Even pet owners are becoming more and more aware of animal health. Byotrol sells sprays that disinfect areas where pets have been and remove odors from dog baskets and the like. Veterinarians use Byotrol disinfectants to make sure their surfaces are always clean. The group even makes a lavender-based shampoo for the Pets at Home retail group so the dogs can smell nice and stay germ-free.
Byotrol also makes its own brand of hand sanitizer, Invirtu, which is also alcohol-free and very popular with specialty retailers.
Byotrol's fiscal year runs through March 31st. The verified figures will be published in a few weeks.
However, in the past few months Traynor has released three dynamic trading updates, each of which generated an update to the broker forecast.
Analysts now expect revenue of £ 6 million through March 2020, plus a small loss as excess cash has been reinvested in the business.
For the current year a turnover of 11.5 million GBP and a profit of 1.5 million GBP is expected.
Looking to the future, the outlook for the group is good. Tighter regulations are restricting the supply of sanitary products, while Covid-19 has drastically changed demand.
Byotrol has done well with the legislators so far and is looking for environmentally friendly products for the future, such as B. Algae-based cleaning solutions that appear to have antiviral properties.
In fact, it seems that insurers insist that certain approved products be used in the workplace before offering policies to business customers.
Midas conclusion : Byotrol has made great strides this year, but the best is yet to come. Traynor has also built a strong Board of Directors, a team of six that includes a former AstraZeneca Vice President and two former Unilever Executive Directors. At 5.9 pence, Byotrol's stock is a buy.
Negotiated under: AIM Ticker: BYOT Contact: byotrolplc.com or 01925 742000
Aucun commentaire:
Enregistrer un commentaire